Benzinga | Jun 4, 2021 08:08AM EDT

Travere Therapeutics Highlights Abstract Presentations At European Renal Association European Dialysis and Transplant Association Congress Jun. 5-7

Travere Therapeutics (NASDAQ:TVTX) today announced presentations including nonclinical data examining the renal protective effects of sparsentan, a high affinity antagonist of both endothelin type A (ETA) and angiotensin II type 1 (AT1) receptors, in focal segmental glomerulosclerosis (FSGS) mouse models, at the 58th European Renal Association -- European Dialysis and Transplant Association (ERA-EDTA) Congress. The Company and its collaborators will also present analyses from independent randomized controlled studies and registries exploring the beneficial treatment effects of reducing proteinuria in FSGS and IgA nephropathy. ERA-EDTA is being held virtually June 5-8, 2021.

Oral Presentations:

Sparsentan improves glomerular blood flow and augments protective tissue remodeling in mouse models of focal segmental glomerulosclerosis

Presentation #: MO1132

Session Title: Pathology meets clinics

Date & Time Monday, June 7, 2021, 17:00-18:30 CEST

Estimating delay in time to ESKD for treatment effects on proteinuria in IgA nephropathy and FSGS

Presentation #: MO246

Session: Moderated Mini-Orals 2

Date & Time Sunday, June 6, 2021, 16:30-17:45 CEST

The treatment effect of RAS blockade on proteinuria in IgA nephropathy patients as a surrogate for renal events and decline in eGFR: An analysis of randomized controlled trials

Presentation #: MO256

Session: Glomerulonephritis

Date & Time Available beginning June 5, 2021